Search Results - "Kosh, Michele"

Pembrolizumab versus Ipilimumab in Advanced Melanoma by Robert, Caroline, Schachter, Jacob, Long, Georgina V., Arance, Ana, Grob, Jean Jacques, Mortier, Laurent, Daud, Adil, Carlino, Matteo S., McNeil, Catriona, Lotem, Michal, Larkin, James, Lorigan, Paul, Neyns, Bart, Blank, Christian U., Hamid, Omid, Mateus, Christine, Shapira-Frommer, Ronnie, Kosh, Michele, Zhou, Honghong, Ibrahim, Nageatte, Ebbinghaus, Scot, Ribas, Antoni

Get full text

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS by Moreau, Philippe, Chari, Ajai, Oriol, Albert, Martinez-Lopez, Joaquin, Haenel, Mathias, Touzeau, Cyrille, Ailawadhi, Sikander, Besemer, Britta, de la Rubia Comos, Javier, Encinas, Cristina, Mateos, Maria-Victoria, Salwender, Hans, Rodriguez-Otero, Paula, Hulin, Cyrille, Karlin, Lionel, Sureda Balari, Anna, Bargay, Joan, Benboubker, Lotfi, Rosiñol, Laura, Tarantolo, Stefano, Terebelo, Howard, Yang, Shiyi, Wang, Jianping, Nnane, Ivo, Qi, Ming, Kosh, Michele, Delioukina, Maria, Goldschmidt, Hartmut

Get full text

Pembrolizumab versus Ipilimumab in Advanced Melanoma by Robert, Caroline, Schachter, Jacob, Long, Georgina V, Arance, Ana, Grob, Jean Jacques, Mortier, Laurent, Daud, Adil, Carlino, Matteo S, McNeil, Catriona, Lotem, Michal, Larkin, James, Lorigan, Paul, Neyns, Bart, Blank, Christian U, Hamid, Omid, Mateus, Christine, Shapira-Frommer, Ronnie, Kosh, Michele, Zhou, Honghong, Ibrahim, Nageatte, Ebbinghaus, Scot, Ribas, Antoni

“…In a multinational, randomized study, pembrolizumab produced significantly improved progression-free and overall survival and less high-grade toxicity than did…”
Get full text

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study by Chari, Ajai, Rodriguez‐Otero, Paula, McCarthy, Helen, Suzuki, Kenshi, Hungria, Vania, Sureda Balari, Anna, Perrot, Aurore, Hulin, Cyrille, Magen, Hila, Iida, Shinsuke, Maisnar, Vladimir, Karlin, Lionel, Pour, Ludek, Parasrampuria, Dolly A., Masterson, Tara, Kosh, Michele, Yang, Shiyi, Delioukina, Maria, Qi, Ming, Carson, Robin, Touzeau, Cyrille

“…Summary Daratumumab is a CD38‐targeting monoclonal antibody approved for intravenous (IV) infusion for multiple myeloma (MM). We describe the Phase II PLEIADES…”
Get full text

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study by Dimopoulos, Meletios A., Terpos, Evangelos, Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Baldini, Luca, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria-Victoria, Einsele, Hermann, Orfanidis, Ioannis, Kampfenkel, Tobias, Liu, Weiping, Kosh, Michele, Tran, NamPhuong, Carson, Robin, Sonneveld, Pieter

Get full text

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study by Sonneveld, Pieter, Terpos, Evangelos, Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Baldini, Luca, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria-Victoria, Einsele, Hermann, Orfanidis, Ioannis, Kampfenkel, Tobias, Qiu, Yanping, Amin, Himal, Kosh, Michele, Tran, NamPhuong, Carson, Robin, Dimopoulos, Meletios A.

“…Introduction: Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. DARA is…”
Get full text

Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES) by Chari, Ajai, Goldschmidt, Hartmut, yang, shiyi, Kosh, Michele, Delioukina, Maria, Qi, Ming, Moreau, Philippe

Get full text

Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts by Moreau, Philippe, Chari, Ajai, Haenel, Mathias, Oriol, Albert, Rodriguez-Otero, Paula, McCarthy, Helen, Suzuki, Kenshi, Hungria, Vania T.M., Sureda Balari, Anna, Clement-Filliatre, Lauriane, Hulin, Cyrille, Magen, Hila, Iida, Shinsuke, Maisnar, Vladimir, Karlin, Lionel, Pour, Luděk, Touzeau, Cyrille, Yang, Shiyi, Kosh, Michele, Delioukina, Maria, Heuck, Christoph, Goldschmidt, Hartmut

“…Introduction: DARA is a human IgGκ monoclonal antibody targeting CD38 and is approved for intravenous (IV) infusion across lines of therapy for MM. In phase 3…”
Get full text

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update by Chari, Ajai, San-Miguel, Jesús, McCarthy, Helen, Suzuki, Kenshi, Hungria, Vania T.M., Sureda, Anna, Perrot, Aurore, Hulin, Cyrille, Magen, Hila, Iida, Shinsuke, Maisnar, Vladimir, Karlin, Lionel, Pour, Ludek, Parasrampuria, Dolly A., Masterson, Tara, Kosh, Michele, Yang, Shiyi, Delioukina, Maria L., Qi, Ming, Carson, Robin, Touzeau, Cyrille

“…Introduction: Daratumumab (DARA) 16 mg/kg intravenous (IV) is approved as monotherapy for relapsed or refractory multiple myeloma (RRMM) and in combination…”
Get full text

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial by Dimopoulos, Meletios A, Terpos, Evangelos, Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Baldini, Luca, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria-Victoria, Einsele, Hermann, Orfanidis, Ioannis, Kampfenkel, Tobias, Liu, Weiping, Wang, Jianping, Kosh, Michele, Tran, NamPhuong, Carson, Robin, Sonneveld, Pieter

“…The primary analysis of the APOLLO trial, done after a median follow-up of 16·9 months, showed that daratumumab plus pomalidomide and dexamethasone…”
Get full text

Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES) by Chari, Ajai, Goldschmidt, Hartmut, San-Miguel, Jesus, McCarthy, Helen, Suzuki, Kenshi, Hungria, Vania, Balari, Anna Sureda, Perrot, Aurore, Hulin, Cyrille, Magen, Hila, Iida, Shinsuke, Maisnar, Vladimir, Karlin, Lionel, Pour, Ludek, Parasrampuria, Dolly, Masterson, Tara, Kosh, Michele, yang, shiyi, Qi, Ming, Carson, Robin, Moreau, Philippe

Get full text

Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma by Ribas, Antoni, Schachter, Jacob, Long, Georgina V., Arance, Ana, Grob, Jean Jacques, Mortier, Laurent, Daud, Adil, Carlino, Matteo S., McNeil, Catriona, Lotem, Michal, Larkin, James, Lorigan, Paul, Neyns, Bart, Blank, Christian U., Hamid, Omid, Kosh, Michele, Zhou, Honghong, Ibrahim, Nageatte, Ebbinghaus, Scot, Robert, Caroline

“…Background: Ipilimumab (IPI; anti-CTLA4) and pembrolizumab (PEMBRO; anti-PD-1) are checkpoint inhibitors that stimulate immune responses to cancer. In…”
Get full text